Accelerated neurodegeneration through chaperone-mediated oligomerization of tau
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Aggregation of tau protein in the brain is associated with a class of neurodegenerative diseases known as tauopathies. FK506 binding protein 51 kDa (FKBP51, encoded by FKBP5) forms a mature chaperone complex with Hsp90 that prevents tau degradation. In this study, we have shown that tau levels are reduced throughout the brains of Fkbp5-/- mice. Recombinant FKBP51 and Hsp90 synergized to block tau clearance through the proteasome, resulting in tau oligomerization. Overexpression of FKBP51 in a tau transgenic mouse model revealed that FKBP51 preserved the species of tau that have been linked to Alzheimer's disease (AD) pathogenesis, blocked amyloid formation, and decreased tangle load in the brain. Alterations in tau turnover and aggregate structure corresponded with enhanced neurotoxicity in mice. In human brains, FKBP51 levels increased relative to age and AD, corresponding with demethylation of the regulatory regions in the FKBP5 gene. We also found that higher FKBP51 levels were associated with AD progression. Our data support a model in which age-associated increases in FKBP51 levels and its interaction with Hsp90 promote neurotoxic tau accumulation. Strategies aimed at attenuating FKBP51 levels or its interaction with Hsp90 have the potential to be therapeutically relevant for AD and other tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hsp90:FKBP51 functions in tau proteostasis, increasing its stability and altering phosphorylation states”
From The structure of an Hsp90-immunophilin complex reveals cochaperone recognition of the client maturation state (2021) · cites this paper as Blair et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“since FKBP5 site-specific demethylation occurs with age (49).”
From Holocaust Exposure Induced Intergenerational Effects on FKBP5 Methylation (2016) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Introduction Neurofibrillary tangles, hallmarks of a class of neurodegenerative diseases termed tauopathies, are comprised of microtubule-associated tau protein aggregates that persist in the brain even after neuron death (1).”
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES
Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,487 · cited 2×
“3- to 4-times more abundant in cells than 26S proteasomes (35).”
Whitmore, L., & Wallace, B. A. (2008) · Biopolymers · doi:10.1002/bip.20853 · Cited by 2,243
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · cited 1×
“This same model displays cognitive recovery when tau is suppressed, despite continued tangle formation (5, 46).”
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
The Amyloid State of Proteins in Human Diseases
Eisenberg, D., & Jucker, M. (2012) · Cell · doi:10.1016/j.cell.2012.02.022 · Cited by 1,744
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“However, levels of neuronal death in AD far exceed what is expected based on the observed numbers of tau tangles (2), suggesting that a different mechanism is primarily responsible for neurodegeneration.”
Cited by
Items 101–200 of 324
SARS-CoV-2 infection increases the gene expression profile for Alzheimer’s disease risk
Green, R. J., Mayilsamy, K., McGill, A. R., Martinez, T. E., Chandran, B., Blair, L. J., Bickford, P. C., Mohapatra, S. S., & Mohapatra, S. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.007 · Cited by 45
Self-citationRescue from tau-induced neuronal dysfunction produces insoluble tau oligomers
Cowan, C. M., Quraishe, S., Hands, S., Sealey, M., Mahajan, S., Allan, D. W., & Mudher, A. (2015) · Scientific Reports · doi:10.1038/srep17191 · Cited by 39
Azure C Targets and Modulates Toxic Tau Oligomers
Lo Cascio, F., & Kayed, R. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00501 · Cited by 39
Self-citationOkuda, M., Hijikuro, I., Fujita, Y., Wu, X., Nakayama, S., Sakata, Y., Noguchi, Y., Ogo, M., Akasofu, S., Ito, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117511 · Cited by 41
“Overexpression of FKBP51 by AAV9 injection increased tau oligomer levels inducing neuronal toxicity in transgenic mice [44].”
BackgroundEffects of chronic variable stress on cognition and Bace1 expression among wild-type mice
Cordner, Z. A., & Tamashiro, K. L. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.127 · Cited by 41
Ye, S., Wang, D., Xu, Y., Wang, C., Cao, L., Liu, Y., & Zhu, C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150486 · Cited by 38
Nadel, C. M., Thwin, A. C., Callahan, M., Lee, K., Connelly, E. J., Craik, C. S., Southworth, D. R., & Gestwicki, J. E. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168026 · Cited by 35
Alzheimer's disease‐causing proline substitutions lead to presenilin 1 aggregation and malfunction
Ben‐Gedalya, T., Moll, L., Bejerano‐Sagie, M., Frère, S. G. A., Cabral, W. A., Friedmann‐Morvinski, D., Slutsky, I., Burstyn‐Cohen, T., Marini, J. C., & Cohen, E. (2015) · The EMBO Journal · doi:10.15252/embj.201592042 · Cited by 38
“In contrast, FKBP51 was reported to enhance proteotoxicity and to be more abundant in brains of old individuals and patients with AD than in those of healthy controls (Blair et al , 2013).”
Mechanisms of protein homeostasis in health, aging and disease
Goloubinoff, P. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14306 · Cited by 38
Roe, S. M., Wahab, B., Török, Z., Horváth, I., Vígh, L., & Prodromou, C. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00051 · Cited by 36
“Tau accumulation and aggregation is facilitated by Hsp90 (Blair et al., 2013), and consequently efforts are directed toward developing Hsp90 inhibitors that promote Tau degradation (Dickey et al.”
BackgroundFunctions of the Hsp90-Binding FKBP Immunophilins
Guy, N. C., Garcia, Y. A., Sivils, J. C., Galigniana, M. D., & Cox, M. B. (2015) · Subcellular Biochemistry · doi:10.1007/978-3-319-11731-7_2 · Cited by 35
“demonstrated that upregulation of FKBP51 expression is attributed to a decrease in FKBP5 methylation in which the process appears to be inversely proportional over time (Blair et al. 2013).”
BackgroundMeng, G., Zhong, X., & Mei, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150624 · Cited by 36
“In this step , we found three microarray experiments with good quality : GSE5281 [ 23 ] , GSE26972 [ 24 ] , GSE48350 [ 25 ] .”
Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer’s disease
Davis, M. R., Robinson, E., Koronyo, Y., Salobrar‐García, E., Rentsendorj, A., Gaire, B. P., Mirzaei, N., Kayed, R., Sadun, A. A., Ljubimov, A. V., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-01935-y · Cited by 37
Self-citationIsoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma
Stothert, A. R., Suntharalingam, A., Tang, X., Crowley, V. M., Mishra, S. J., Webster, J. M., Nordhues, B. A., Huard, D. J. E., Passaglia, C. L., Lieberman, R. L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18344-4 · Cited by 35
Self-citationChiou, K. L., DeCasien, A. R., Rees, K. P., Testard, C., Spurrell, C. H., Gogate, A. A., Pliner, H. A., Tremblay, S., Mercer, A., Whalen, C. J., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01197-0 · Cited by 37
Gupta, C., Xu, J., Jin, T., Khullar, S., Liu, X., Alatkar, S., Cheng, F., & Wang, D. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010287 · Cited by 33
“Level of FKBP5 was found to be positively correlated with AD development and FKBP5’s interaction with Hsp90 accelerated tau aggregation [63].”
BackgroundSKA2 regulated hyperactive secretory autophagy drives neuroinflammation-induced neurodegeneration
Hartmann, J., Bajaj, T., Otten, J., Klengel, C., Ebert, T., Gellner, A., Junglas, E., Hafner, K., Anderzhanova, E. A., Tang, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46953-x · Cited by 38
“Along theselines, increased FKBP5 expression haspreviously been linked to AD in several brain regions, and higher FKBP5 levels were associated with AD progression 39 .”
Self-citationJung, C., Kato, R., Zhou, C., Abdelhamid, M., Shaaban, E. I. A., Yamashita, H., & Michikawa, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-16626-0 · Cited by 41
Di Sante, J., Ismaylova, E., Nemoda, Z., Gouin, J.-P., Yu, W.-J., Caldwell, W., Vitaro, F., Szyf, M., Tremblay, R. E., & Booij, L. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.07.019 · Cited by 31
The metamorphic nature of the Tau protein: dynamic flexibility comes at a cost
Sabbagh, J. J., & Dickey, C. A. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00003 · Cited by 31
“Because the dynamic chaperone landscape changes with age and especially AD (Yoo et al., 2001; Jinwal et al., 2010; Blair et al., 2013), it is likely that dysfunction in the ability of Hsp70 or Hsp90 to regulate tau contributes to its misfolding and aggregation.”
BackgroundMethodInfluentialSelf-citationHippocampal Neurogenesis Is Enhanced in Adult Tau Deficient Mice
Criado‐Marrero, M., Sabbagh, J. J., Jones, M. R., Chaput, D., Dickey, C. A., & Blair, L. J. (2020) · Cells · doi:10.3390/cells9010210 · Cited by 34
“In addition, high FKBP5 levels have also been shown to be found in the AD brain and can preserve neurotoxic tau [91].”
BackgroundSelf-citationPregnancy as a model for aging
Giller, A., Andrawus, M., Gutman, D., & Atzmon, G. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101093 · Cited by 38
van Doeselaar, L., Stark, T., Mitra, S., Yang, H., Bordes, J., Stolwijk, L., Engelhardt, C., Kovarova, V., Narayan, S., Brix, L. M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300722120 · Cited by 30
“Since the discovery of FKBP5 as a key genetic risk factor for psychiatric disease (13), a vast amount of work has been put in trying to unravel the exact mechanisms by which it contributes to stress susceptibility and resilience (18–20, 22–27, 31, 32, 49, 50).”
Shi, H., Mirzaei, N., Koronyo, Y., Davis, M. R., Robinson, E., Braun, G. M., Jallow, O., Rentsendorj, A., Ramanujan, V. K., Fert‐Bober, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02760-8 · Cited by 35
“These oligomers can propagate to healthy neurons and spread the disease [12, 26, 32, 42, 49, 52].”
BackgroundSelf-citationBreydo, L., Redington, J., & Uversky, V. N. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.08.011 · Cited by 32
Self-citationAminyavari, S., Zahmatkesh, M., Khodagholi, F., & Sanati, M. (2019) · Peptides · doi:10.1016/j.peptides.2019.170102 · Cited by 30
Domains of STIP1 responsible for regulating PrPC-dependent amyloid-β oligomer toxicity
Maciejewski, A., Ostapchenko, V. G., Beraldo, F. H., Prado, V. F., Prado, M. A. M., & Choy, W. (2016) · Biochemical Journal · doi:10.1042/bcj20160087 · Cited by 33
Lackie, R. E., de Miranda, A. S., Lim, M. P., Novikov, V., Madrer, N., Karunatilleke, N. C., Rutledge, B. S., Tullo, S., Brickenden, A. M., Maitland, M. E. R., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02491-8 · Cited by 34
“Notably, Hsp90 co-chaperones FKBP51 and Aha1 stabilize toxic tau conformers and augment tau aggregation in vitro and in vivo, respectively [18, 36, 66].”
BackgroundAlmeida, M. C., Eger, S. J., He, C., Audouard, M., Nikitina, A. A., Glasauer, S. M. K., Han, D., Mejía‐Cupajita, B., Acosta‐Uribe, J., Villalba‐Moreno, N. D., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.02.009 · Cited by 35
Schirmer, C., Lepvrier, E., Duchesne, L., Decaux, O., Thomas, D., Delamarche, C., & Garnier, C. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.07.033 · Cited by 29
Mao, Y., Fisher, D. W., Yang, S., Keszycki, R. M., & Dong, H. (2020) · PLOS ONE · doi:10.1371/journal.pone.0226021 · Cited by 28
“While HSP70 has been shown to increase p-tau degradation and stabilize tau binding to microtubules[66–68], HSP90 may actually maintain oligomeric p-tau levels, which are quite pathogenic[69, 70].”
BackgroundAltered DNA methylation profiles in blood from patients with sporadic Creutzfeldt–Jakob disease
Dabin, L. C., Guntoro, F., Campbell, T., Bélicard, T., Smith, A. R., Smith, R. G., Raybould, R., Schott, J. M., Lunnon, K., Sarkies, P., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02224-9 · Cited by 32
“Given the previously reported link between FKBP5 and neurodegeneration [5], our finding that the promoter of FKBP5 is demethylated in sCJD (Fig.”
BackgroundStructural Basis for Chaperone‐Independent Ubiquitination of Tau Protein by Its E3 Ligase CHIP
Munari, F., Mollica, L., Valente, C., Parolini, F., Kachoie, E. A., Arrigoni, G., D’Onofrio, M., Capaldi, S., & Assfalg, M. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202112374 · Cited by 27
Giannos, P., Prokopidis, K., Raleigh, S. M., Kelaiditi, E., & Hill, M. W. (2022) · Scientific Reports · doi:10.1038/s41598-022-15578-9 · Cited by 29
Friend or foe: role of pathological tau in neuronal death
Wu, M., Chen, Z., Jiang, M. H., Bao, B., Li, D., Yin, X., Wang, X., Liu, D., & Zhu, L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02024-z · Cited by 30
“In addition, FKBP51, another homolog of FKBP52, formed mature chaperone complexes with Hsp90 machinery to block tau clearance in the aged and AD brain through proteasomes, connecting this protein to speci fi c cell death [165].”
Shields, A. E. (2017) · Epigenomics · doi:10.2217/epi-2017-0013 · Cited by 29
Inhibition of excessive kallikrein-8 improves neuroplasticity in Alzheimer's disease mouse model
Münster, Y., Keyvani, K., & Herring, A. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113115 · Cited by 31
Altınok, S., Sanchez‐Hodge, R., Stewart, M., Smith, K., & Schisler, J. C. (2021) · Cells · doi:10.3390/cells10113121 · Cited by 28
“showed that tau levels were reduced in Fkbp51 knockout mouse brains, whereas overexpression of FKBP51 in the tau transgenic mouse model resulted in the accumulation of tau oligomers [228].”
BackgroundAlzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
Nystuen, K., McNamee, S. M., Akula, M., Holton, K. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11010045 · Cited by 29
Isolation and characterization of antibody fragments selective for toxic oligomeric tau
Tian, H., Davidowitz, E. J., Lopez, P. L. D. C., He, P., Schulz, P., Moe, J. G., & Sierks, M. R. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.002 · Cited by 28
“…studies to elucidate the roles of different variants and aggregate forms of tau (Berger et al., 2007, LasagnaReeves et al., 2010, Lasagna-Reeves et al., 2012b, Ward et al., 2012, Blair et al., 2013, Cohen et al., 2013, Cowan and Mudher, 2013, Gerson and Kayed, 2013, Yanamandra et al., 2013).”
BackgroundTherapeutic and diagnostic challenges for frontotemporal dementia
Dâ€TMAlton, S., & Lewis, J. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00204 · Cited by 26
“For example, heatshock protein mediated stabilization of oligomers in the rTg4510 model of tauopathy is associated with enhanced neurotoxicity but reduced fibril formation (Blair et al., 2013).”
BackgroundMartin, M. D., Calcul, L., Smith, C., Jinwal, U. K., Fontaine, S. N., Darling, A. L., Seeley, K. W., Wojtas, Ł., Narayan, M., Gestwicki, J. E., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501013w · Cited by 26
Self-citationHeterogeneous Tau Oligomers as Molecular Targets for Alzheimer’s Disease and Related Tauopathies
Lo, C. H. (2022) · Biophysica · doi:10.3390/biophysica2040039 · Cited by 25
“While the cellular system has the dvantage of being physiologically r levant as well as c ntaining the cellular components s ch as numerous chaperone proteins [57], caspases [58], and kinases [59] that play key roles in tau oligomerization [60], it is difficult to capture the biophysical characterizations as well as d…”
The proteostasis network provides targets for neurodegeneration
Newton, T. M., Duce, J. A., & Bayle, E. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14643 · Cited by 25
Agam, G., Atawna, B., Damri, O., & Azab, A. N. (2024) · Cells · doi:10.3390/cells13100801 · Cited by 26
Tangavelou, K., & Bhaskar, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212335 · Cited by 25
“However, when heat shock protein 90 kDa (HSP90) interacts with FK506 binding protein 51 kDa (FKBP51), a cochaperone inhibits the 20S proteasomal activity and favors tau to oligomerize, which exacerbates neurotoxicity in rTg(tauP301L)4510 mice [33] (Figure 3B).”
Identification of dysregulated genes and pathways of different brain regions in Alzheimer’s disease
Wang, Y., & Wang, Z. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1720677 · Cited by 23
Beach, S. R. H., Ong, M. L., Lei, M., Carter, S. E., Simons, R. L., Gibbons, F. X., & Philibert, R. A. (2021) · Epigenetics · doi:10.1080/15592294.2021.1980688 · Cited by 24
The role of the FKBP51–Hsp90 complex in Alzheimer’s disease: An emerging new drug target
Jeanne, X., Török, Z., Vígh, L., & Prodromou, C. (2024) · Cell Stress and Chaperones · doi:10.1016/j.cstres.2024.11.006 · Cited by 24
Sree, G. N. S. H., Rajalekshmi, S. G., & Burri, R. R. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01919-2 · Cited by 21
Small Heat Shock Protein 22 Improves Cognition and Learning in the Tauopathic Brain
Ospina, S. R., Blazier, D. M., Criado‐Marrero, M., Gould, L. A., Gebru, N. T., Beaulieu‐Abdelahad, D., Wang, X., Remily-Wood, E. R., Chaput, D., Stevens, S. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020851 · Cited by 23
“Gallyas silver-staining method was performed as previously described [24,72,73].”
MethodSelf-citationStressing Out Hsp90 in Neurotoxic Proteinopathies
Inda, C., Bolaender, A., Wang, T., Gandu, S. R., & Koren, J. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160413141350 · Cited by 21
“Blair continues this by demonstrating that tau-transgenic mice lacking FKBP51 have reduced tau levels; specifically reducing a specific tau oligomer [22].”
Background“In the flesh”: Narratives of family caregivers at risk of Early-onset Familial Alzheimer’s Disease
García-Toro, M., Gómez, M. C. S., Madrigal, L., & Lopera, F. J. (2018) · Dementia · doi:10.1177/1471301218801501 · Cited by 25
“First, these caregivers may be at risk of accelerating the onset of symptoms when exposed to situations of emotional stress (Bengtsson, 2013; Blair et al., 2013; Mah, Szabuniewicz, & Fiocco, 2016) and second, the onset of the symptoms of Alzheimer’s Disease could create overlap.”
BackgroundKey Physicochemical and Biological Factors of the Phase Behavior of Tau
Nam, G., Lin, Y., Lim, M. H., & Lee, Y. (2020) · Chem · doi:10.1016/j.chempr.2020.09.012 · Cited by 23
García-Gómara, M., Legarra-Marcos, N., Serena, M., Rojas-de-Miguel, E., Espelosin, M., Marcilla, I., Pérez‐Mediavilla, A., Luquín, M. R., Lanciego, J. L., Burrell, M. A., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.049 · Cited by 21
Wang, L., Bergkvist, L., Kumar, R., Winblad, B. G., & Pavlov, P. F. (2021) · Cells · doi:10.3390/cells10102596 · Cited by 25
“Increases with age in the mouse brain, and its expression is higher in AD patients [55,56].”
BackgroundInfluentialSelf-citationBoe, D. M., Hulsebus, H. J., Najarro, K. M., Mullen, J. E., Kim, H., Tan, A. C., McMahan, R. H., & Kovacs, E. J. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.3hi0620-399rr · Cited by 20
The emerging importance of immunophilins in fibrosis development
Alqudah, A. M., Abudalo, R. A., Qnais, E. Y., Wedyan, M. A., Oqal, M. K., & McClements, L. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04591-1 · Cited by 20
Jiang, L., Chakraborty, P., Zhang, L., Wong, M., Hill, S. E., Webber, C. J., Libera, J., Blair, L. J., Wolozin, B. L., & Zweckstetter, M. (2023) · Science Advances · doi:10.1126/sciadv.add9789 · Cited by 21
Self-citationTau13 Antibody Preferentially Immunoprecipitates High Molecular Weight Tau Proteins
Umstead, A., & Vega, I. E. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181187 · Cited by 18
“For example, FKBP51/Hsp90 chaperone complex block UPS-mediated tau degradation and induce the formation of oligomeric tau, promoting tau-mediated neurotoxicity [9].”
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2200245 · Cited by 21
Beach, S. R. H., Gibbons, F. X., Carter, S. E., Ong, M. L., Lavner, J. A., Lei, M.-K., Simons, R. L., Gerrard, M., & Philibert, R. A. (2022) · Development and Psychopathology · doi:10.1017/s0954579421001541 · Cited by 18
“FKBP5 expression is associated with regulation of inflammatory activity (e.g., Erlejman et al., 2014; Maiarù et al., 2016) and accelerated aging of the brain (Blair et al., 2013; Jinwal et al., 2010).”
BackgroundFKBP52 in Neuronal Signaling and Neurodegenerative Diseases: A Microtubule Story
Chambraud, B., Byrne, C., Méduri, G., Baulieu, E. E., & Giustiniani, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031738 · Cited by 19
“It has been reported that Hsp90 regulates Tau function [115,116] and synergizes with FKBP51 to block Tau degradation resulting in Tau oligomerization under pathological conditions [63,114].”
BackgroundResultRoe, S. M., Török, Z., McGown, A., Horváth, I., Spencer, J., Pázmány, T., Vígh, L., & Prodromou, C. (2023) · Biomolecules · doi:10.3390/biom13071051 · Cited by 17
“Previous studies suggest that FKBP51 increases with age and stress and increases even further with AD disease, and it significantly increases the hyperphosphorylation of tau [25,27].”
BackgroundPeak, S. L., Gracia, L., Lora, G., & Jinwal, U. K. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.020 · Cited by 18
Keegan, B. M., Catalfano, K. C., Banerjee, M., & Blagg, B. S. J. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00064 · Cited by 16
Chaperoning activity of the cyclophilin family prevents tau aggregation
Hill, S. E., Esquivel, A. R., Ospina, S. R., Rahal, L. M., Dickey, C. A., & Blair, L. J. (2022) · Protein Science · doi:10.1002/pro.4448 · Cited by 16
“In relation to physiological tau, turnover is driven by ubiquitin-dependent proteasome degradation,(38) although ubiquitinindependent 20S proteasome degradation can also contribute.(13) Thus, it is possible PPIC, PPIE, and PPIF stabilize tau in a more disordered state enhancing effective proteolytic break down.”
BackgroundSelf-citationFrontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies
Li, Y., Tan, M., Yu, J., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9507-5 · Cited by 21
“Heat-shock protein 90 (Hsp90) system is of interest as a potential tau Btoxifier^ because inhibition of Hsp90 promotes tau clearance, and recombinant FKBP51 and Hsp90 synergize to block tau clearance through the proteasome, eventually resulting in tau oligomerization [60].”
BackgroundSRCP1 Conveys Resistance to Polyglutamine Aggregation
Santarriaga, S., Haver, H. N., Kanack, A. J., Fikejs, A. S., Sison, S. L., Egner, J. M., Bostrom, J. R., Seminary, E. R., Hill, R. B., Link, B. A., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.07.008 · Cited by 16
“Alternatively, some proteins, like the neurodegenerative disease protein tau, are degraded in the absence of ubiquitination (Blair et al., 2013; David et al., 2002; Grune et al., 2010).”
BackgroundSelf-citationHong, H., Mo, Y., Li, D., Xu, Z., Liao, Y., Yin, P., Liu, X., Xia, Y., Fang, J., Wang, Q., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.02.008 · Cited by 17
Post-translational modifications and stress adaptation: the paradigm of FKBP51
Rein, T. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190332 · Cited by 16
Gazzina, S., Manes, M. A., Padovani, A., & Borroni, B. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.056 · Cited by 22
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes
Futch, H. S., McFarland, K. N., Moore, B. D., Kuhn, M. Z., Giasson, B. I., Ladd, T. B., Scott, K. A., Shapiro, M. R., Nosacka, R. L., Goodwin, M. S., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190430 · Cited by 20
“…of CTRND05, we do see large-scale alterations in gene expression and down-regulation of the mRNA for the key GR chaperone FKBP5 in the brain, which is a target in major depression and may have other interesting chaperone functions relevant to tauopathy and neurodegeneration (Blair et al., 2013).”
Self-citationMeredith, M., Daida, K., Moller, A., Jerez, P. Á., Negi, S., Malik, L., Genner, R. M., Zheng, X., Gibson, S. B., Mastoras, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.16.628723 · Cited by 22
“Interestingly overexpression of FKBP5 may also play a role in Tau protein accumulation which is linked to AD 48 .”
Morderer, D., Wren, M. C., Liu, F., Kouri, N., Maistrenko, A., Khalil, B., Pobitzer, N., Salemi, M., Phinney, B. S., Bu, G., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00817-0 · Cited by 23
Genetically engineered mouse models of FK506‐binding protein 5
Gebru, N. T., Hill, S. E., & Blair, L. J. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30374 · Cited by 17
Self-citationWei, X., Du, P., & Zhao, Z. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136196 · Cited by 15
From Small Peptides to Large Proteins against Alzheimer’sDisease
Picone, P., Sanfilippo, T., Vasto, S., Baldassano, S., Guggino, R., Nuzzo, D., Bulone, D., Biagio, P. L. S., Muscolino, E., Monastero, R., et al. (2022) · Biomolecules · doi:10.3390/biom12101344 · Cited by 18
Singh, M. K., Ranbhise, J. S., Fu, M., Ju, S., Han, S., Yun, H. R., Choe, W., Kim, S. S., & Kang, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110279 · Cited by 16
Wen, H., He, Y., Tang, Y., Zhu, L., Tao, Q., Jin, B., Luo, T., Peng, Y., Wei, Y., Lei, J., et al. (2024) · Brain Pathology · doi:10.1111/bpa.13318 · Cited by 14
“The expression of FKBP5 increases with age and the progression of AD, and its inhibitory role in the clearance of tau proteins reveals its close association with the course of AD [71].”
Self-citationLong non‐coding RNAs as key regulators of neurodegenerative protein aggregation
Xu, Q., Liu, D., Zhu, L., Su, Y., & Huang, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14498 · Cited by 18
Role of frameshift ubiquitin B protein in Alzheimer's disease
Chen, X., & Petranović, D. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1340 · Cited by 18
“The FK506 binding protein 51 kDa (FKBP51) forms a mature chaperone complex with Hsp90 that blocks tau clearance through the proteasome, resulting in tau oligomerization.(51)”
BackgroundKuznetsova, I. L., Пономарева, Н. В., Alemastseva, E. A., Manakhov, A. D., Andreeva, T. V., Gusev, F. E., & Rogaev, E. I. (2022) · Genes · doi:10.3390/genes13020164 · Cited by 17
“In mice, the chaperone FKBP51 can work with Hsp90 to produce tau protein, facilitating its neurotoxicity [38].”
BackgroundFKBP51 modulates hippocampal size and function in post-translational regulation of Parkin
Qiu, B., Zhong, Z., Righter, S., Xu, Y., Wang, J., Deng, R., Wang, C., Williams, K. E., Ma, Y., Tsechpenakis, G., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04167-8 · Cited by 14
“Consistently, previous studies have demonstrated reduced expression of Tau in Fkbp51 KO [6], 7.”
ResultCriado‐Marrero, M., Gebru, N. T., Gould, L. A., Blazier, D. M., Vidal-Aguiar, Y., Smith, T. M., Abdelmaboud, S. S., Shelton, L. B., Wang, X., Dahrendorff, J., et al. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00062-x · Cited by 15
Self-citationAkgüller, Ö., Balcı, M. A., & Cioca, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010003 · Cited by 16
Integrated analysis and identification of hub genes as novel biomarkers for Alzheimer’s disease
Zhao, K., Zhang, H., Wu, Y., Liu, J., Li, X., & Lin, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.901972 · Cited by 18
Structural and biochemical insights into FKBP51 as a Hsp90 co‐chaperone
Baischew, A., Engel, S., Geiger, T. M., Taubert, M. C., & Hausch, F. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30384 · Cited by 15
Soto, O. B., Ramirez, C. S., Koyani, R. D., Rodriguez‐Palomares, I. A., Dirmeyer, J. R., Grajeda, B. I., Roy, S., & Cox, M. B. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30406 · Cited by 15
Wu, C., & Feng, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1097067 · Cited by 17
The role of wild-type tau in Alzheimer’s disease and related tauopathies
Lo, C. H., & Sachs, J. N. (2020) · JoLS Journal of Life Sciences · doi:10.36069/jols/20201201 · Cited by 24
“Despite the ability to induce toxicity, these systems do not recapitulate the cellular environment, lacking the numerous chaperone proteins that may be required to produce the ensemble of tau oligomers that populate the fibrillogenesis cascade [55, 56].”
BackgroundLiu, Y., Lian, J., Fu, Y., Wang, S., Liu, Y., Zhang, R., & Han, H. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100762 · Cited by 13
“Given the established inverse correlation between FKBP5 methylation and expression (Blair et al., 2013), childhood adversity-induced deme-thylation mechanistically drives FKBP5 upregulation — a pathogenic pathway mediating MDD development.”
Small molecules targeting molecular chaperones for tau regulation: Achievements and challenges
He, C., Gu, J., Wang, D., Wang, K., Wang, Y., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115859 · Cited by 14
Self-citationStress Molecular Signaling in Interaction With Cognition
Lugenbühl, J. F., Viho, E. M. G., Binder, E. B., & Daskalakis, N. P. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.09.023 · Cited by 13
“FKBP51 has been shown to alter tau degradation, possibly contributing to tau aggregates observed in neurodegenerative diseases (98).”
Self-citationWang, N., Zhang, Y., Li, X., & Jin, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01026 · Cited by 12
Dubnikov, T., & Cohen, E. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00048 · Cited by 15
Terrelonge, M., LaHue, S. C., Tang, C., Movsesyan, I., Pullinger, C. R., Dubal, D. B., Leung, J. M., & Douglas, V. C. (2022) · Scientific Reports · doi:10.1038/s41598-021-04416-z · Cited by 16
Identification of TAC1 Associated with Alzheimer’s Disease Using a Robust Rank Aggregation Approach
Zhu, M., Tang, M., & Du, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220950 · Cited by 14
Siangphoe, U., & Archer, K. J. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw050 · Cited by 19
Shemesh, N., Shai, N., Meshnik, L., Katalan, R., & Ben‐Zvi, A. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00101 · Cited by 14
“Moreover, changes in chaperone expression levels can disrupt cellular proteostasis and induce an accumulation of damaged protein (Blair et al., 2013; Guisbert et al., 2013; van Oosten-Hawle et al., 2013; Frumkin et al., 2014; Bar-Lavan et al., 2016; Lechler et al., 2017).”
Background
Metadata
- Authors
- Blair, L. J., Nordhues, B. A., Hill, S. E., Scaglione, K. M., O’Leary, J. C., Fontaine, S. N., Breydo, L., Zhang, B., Li, P., Wang, L., Cotman, C., Paulson, H. L., Muschol, M., Uversky, V. N., Klengel, T., Binder, E. B., Kayed, R., Golde, T. E., Berchtold, N., & Dickey, C. A.
- Affiliations
- University of South Florida (US)
- University of Michigan (US)
- University of California, Irvine (US)
- Max Planck Institute of Psychiatry (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Florida (US)
- Corresponding author
- Wang, Li
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-09-03
- Volume
- 123
- Issue
- 10
- Pages
- 4158-4169
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3784538
- OpenAlex
- W2056613924
- Cited by
- 322
- References
- 72
- Citations by year
- 2026: 24 · 2025: 34 · 2024: 25 · 2023: 28 · 2022: 34 · 2021: 20 · 2020: 24 · 2019: 26 · 2018: 19 · 2017: 18 · 2016: 21 · 2015: 24 · 2014: 23 · 2013: 2
- FWCI
- 16.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons - University of South Florida (University of South Florida) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- American Federation for Aging Research
- BrightFocus Foundation
- University of South Florida
- National Institutes of Health
- University of California, Irvine
- National Institute on Aging (P01AG000538, R01AG034667, P50AG016573)
- National Institute of Neurological Disorders and Stroke (K99NS073936, R00NS073936, R01NS073899, NS073899)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau protein, tau oligomerization, tau aggregation, tauopathy, Alzheimer's disease, FKBP51, HSP90, proteasome, tau clearance, amyloid fibril formation, neurotoxicity, tau transgenic mice
- MeSH terms
- Tacrolimus Binding Protein 5, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Female, Gene Expression Regulation, Humans, Male, Middle Aged, Gene Expression, Case-Control Studies, tau Proteins, Mice, Knockout, HSP90 Heat-Shock Proteins, DNA Methylation, Protein Structure, Quaternary, Tacrolimus Binding Proteins, Proteasome Endopeptidase Complex, Mice, Protein Multimerization, Young Adult, CA3 Region, Hippocampal, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.